How Regulation and Reimbursement Can Drive, Not Hinder, the Future of Smart Electronic Skin Patches

James Hayward, principal analyst at IDTechEx, highlights that while electronic skin patches are poised to revolutionize patient monitoring, reimbursement and regulatory frameworks risk stifling innovation.

In their 2019‑2029 report, IDTechEx identified over US$7.5 billion (€6.8 billion) in revenue generated by the technology in 2018, with forecasts exceeding US$20 billion (€18.2 billion) annually over the next decade.

Yet the pace of regulatory approval and reimbursement policies has not kept up. Hayward warns that a market dominated by simplicity and cost can discourage new entrants, even as these devices offer superior effectiveness.

Electronic skin patches are lightweight wearables that embed sensors, processors, actuators and wireless connectivity, allowing continuous, non‑intrusive health data collection. Their popularity surged after 2014, when consumer interest in wearables exploded.

Cardiovascular Monitoring: Reimbursement Roadblocks

Cardiovascular patches compete with consumer wearables—smartwatches and chest straps—that provide cardiac data but lack formal medical validation, and with invasive cardiac implants that are accurate but riskier.

In the U.S., the favorable reimbursement landscape for mobile cardiac telemetry hinged on a Category 3 CPT code for “extended Holter monitoring,” which pays twice as much as “event monitoring” and more than eight times a standard Holter. A shift in this coding could collapse the revenue base for these devices, underscoring how reimbursement shapes product development.

Diabetes Management: A Confusing Landscape

Continuous glucose monitoring (CGM) remains the biggest revenue generator in the patch market, with 2018 sales topping US$2.5 billion (€2.2 billion). The FDA has cleared four CGM systems, three of which use a needle‑based skin patch; one offers a subcutaneous implant paired with a skin‑patch communicator.

All three needle‑based systems are reimbursed under a single regulatory category, receiving identical payments regardless of performance, lifespan or added functionality. This parity risks creating a closed market that favors cheaper, simpler devices over more effective solutions.

The fourth entrant offers a longer‑lasting CGM with distinct features but faces regulatory and reimbursement hurdles that could impede market penetration.

Encouraging Innovation in a Guarded Market

New entrants must navigate stringent regulatory approval—either proving equivalence to existing devices or initiating a de‑novo pathway—before they can compete as medical devices. The high cost and complexity often push innovations into the consumer health space, which offers less reimbursement but lower barriers to entry.

Areas such as fever and fertility monitoring, as well as other patient monitoring technologies, are already witnessing a shift toward consumer‑grade products.

Tracking the Evolution: IDTechEx’s Decade‑Long Analysis

Since 2010, IDTechEx has monitored electronic skin patches across 26 application areas and 100+ market players. Their 2019‑2029 forecast aims to empower healthcare innovators with data‑driven insights for strategic decision‑making.

In addition to their comprehensive reports, IDTechEx is hosting the Healthcare Sensor Innovations 2019 conference in Cambridge, UK—an event that showcases the latest breakthroughs in wearable monitoring and point‑of‑care diagnostics.

Register here

Author: James Hayward, Principal Analyst, IDTechEx

About the Author

James Hayward joined IDTechEx in 2014, spearheading its wearable technology platform. He now leads a multidisciplinary team of analysts covering wearables, sensors, e‑textiles, AR/VR, haptics, displays and advanced materials. James is a frequent speaker at IDTechEx events and international conferences.